To identify novel genes conferring insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer, we performed positive selection (enrichment) genome-wide knockout CRISPR/Cas9 screens in ER+ MCF-7 breast cancer cells (Fig. 1A). This evidence concerns the gene CDK4 and breast carcinoma.